Immunex Enbrel for psoriatic arthritis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Immunex submits Enbrel (entanercept) supplemental BLA July 16 for treatment of signs and symptoms of psoriatic arthritis. FDA will be giving the application priority review "based on need for disease treatment," according to the firm. At this time, there are no therapies for psoriatic arthritis approved in the U.S